Home Cart Sign in  
Chemical Structure| 871361-88-5 Chemical Structure| 871361-88-5

Structure of SC66
CAS No.: 871361-88-5

Chemical Structure| 871361-88-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SC66

CAS No. :871361-88-5
Formula : C18H16N2O
M.W : 276.33
SMILES Code : O=C1/C(CCC/C1=C\C2=CC=NC=C2)=C/C3=CC=NC=C3
MDL No. :MFCD05025493
InChI Key :CYVVJSKZRBZHAV-UNZYHPAISA-N
Pubchem ID :6018993

Safety of SC66

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SC66

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 4 μg/mL 1 h SC66 significantly reduced the phosphorylation level of Akt PMC3081014
HEK293T cells 1, 2, 4 μg/mL 1 h SC66 significantly reduced the phosphorylation level of both Akt and its targets PMC3081014
U87 cells 0, 5, 10, 15, 20, 25, 30 μM 24 h SC66 inhibited U87 cell proliferation with an IC50 value of 10 umol/L PMC7411127
ES-2/CP 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
ES-2 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
OVCAR-8 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
OVCAR-4 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
OVCAR-3 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
HAC-2 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
A2780CP70 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
A2780 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. PMC6459878
5637 cells 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 μM 24 h SC66 significantly inhibited the proliferation of 5637 cells, and the degree of inhibition was positively correlated with the drug concentration. PMC8581318
T24 cells 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 μM 24 h SC66 significantly inhibited the proliferation of T24 cells, and the degree of inhibition was positively correlated with the drug concentration. PMC8581318
Primary human RCC cells 3 μM 24 h SC66 significantly reduced the viability, proliferation, and migration of primary human RCC cells. PMC7214466
A498 cells 3 μM 48-72 h SC66 decreased cell viability and proliferation, and inhibited A498 cell migration and invasion. PMC7214466
786-O cells 1-30 μM 48-96 h SC66 dose-dependently reduced the viability of 786-O cells and significantly decreased the number of viable 786-O cell colonies in soft agar. PMC7214466
HCT-116 WT, HCT-116 p53−/−, DLD1 2 μg/ml 24 h SC66 significantly inhibited the proliferation of HCT-116 WT, HCT-116 p53−/−, and DLD1 cells, and p53 was dispensable in this process. PMC6509835
HCT-116 0.5–4 μg/ml 24 h SC66 significantly inhibited the proliferation of HCT-116 cells in a dose-dependent manner. PMC6509835
U251 cells 0, 5, 10, 15, 20, 25, 30 μM 24 h SC66 inhibited U251 cell proliferation with an IC50 value of 12 umol/L PMC7411127

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD-SCID mice Ovarian cancer xenograft model Intraperitoneal injection 5 mg/kg and 15 mg/kg Once per day for 30 days SC66 treatment significantly inhibited tumor formation and enhanced the therapeutic efficacy of cisplatin. PMC6459878
Balb/c nude mice T24 tumor model Intraperitoneal injection 20 mg/kg Every 2 days for 4 weeks SC66 significantly reduced the weight and volume of T24 tumors in nude mice, and the combination with cisplatin showed better inhibition. PMC8581318
Mice HEK293T cell xenograft model Intraperitoneal injection 15, 30 mg/kg Twice per week for 21 days SC66 significantly inhibited tumor growth PMC3081014
SCID mice 786-O xenograft model Oral 10-25 mg/kg Once daily for 24 days SC66 significantly inhibited the growth of 786-O xenograft tumors, and AKT-mTOR inhibition, SphK1 inhibition, ceramide accumulation, and JNK activation were detected in SC66-treated 786-O xenograft tumors. PMC7214466
Nude mice HCT-116 WT xenograft model Intraperitoneal injection 25 mg/kg Every 3 days for 15 days SC66 significantly inhibited the growth of HCT-116 WT xenograft tumors, with an inhibition rate of about 65%. PMC6509835
Nude mice U87 xenograft tumor model Intraperitoneal injection 25 mg/kg Every 3 days for 6 times SC66 significantly suppressed tumor growth, with tumor weights and volume notably smaller than the control group PMC7411127

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.62mL

0.72mL

0.36mL

18.09mL

3.62mL

1.81mL

36.19mL

7.24mL

3.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories